BioMedNewsBreaks

ThursdayFeb 26, 2026 9:10 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets

Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival,…

Continue Reading

WednesdayFeb 25, 2026 2:07 pm

BioMedNewsBreaks — Anixa Biosciences, Inc. (NASDAQ: ANIX) CAR-T Co-Inventor To Keynote SCTR 2026 Retreat 

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anixa’s CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026. His remarks are expected to include discussion of Anixa’s ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer first discovered at The Wistar Institute, with the study enrolling women who have progressed after at least two…

Continue Reading

WednesdayFeb 25, 2026 9:30 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Expanded IIA Grant Support for Robotic Aseptic Fill & Finish Platform

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that, following additional review by the Israel Innovation Authority, its project to advance a robotic aseptic fill & finish platform has been approved for expanded support, allowing the company to utilize the full approved grant budget of NIS 5 million over two years, approximately 66% of which is non-dilutive funding. The program supports acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026. The investment supports Scinai’s broader CDMO expansion strategy following its acquisition of Recipharm…

Continue Reading

WednesdayFeb 25, 2026 9:10 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach. To view the full press release, visit https://ibn.fm/TToz2 Tonix Pharmaceuticals…

Continue Reading

WednesdayFeb 25, 2026 9:09 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports Multi-Pillar Clinical and Commercial Progress 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms. The company highlighted submission of a manuscript for peer review, showcasing both a new method, Capture-Seq, and new biomarkers for the detection of cancer, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion. Commercialization of the Nu.Q Cancer assay progressed in lung cancer, with the company reporting reimbursement submission in France on track, and routine clinical use expected by Q4 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis and further highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe. The company…

Continue Reading

TuesdayFeb 24, 2026 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website. To view the full press release, visit https://ibn.fm/sOzzL About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical…

Continue Reading

MondayFeb 23, 2026 1:25 pm

BioMedNewsBreaks — HeartSciences Inc. (NASDAQ: HSCS; HSCSW) Secures UWE As Exclusive ECG Education Reference Center 

HeartSciences (NASDAQ: HSCS; HSCSW), a healthcare information technology company advancing electrocardiography through artificial intelligence integration, announced that the University of the West of England has adopted its MyoVista Insights(TM) platform and MyoVista(R) wavECG(TM) device as exclusive ECG technologies to establish an ECG Education and Technology Reference Center. Under the agreement, the technologies will be used across UWE’s cardiac and physiological science programs to train future cardiac scientists, creating a nationally aligned academic reference site that supports clinical adoption discussions with NHS trusts, validates MyoVista Insights in education and research settings, and strengthens the company’s long-term commercial positioning within the UK healthcare ecosystem. To view the full press release, visit https://ibn.fm/fkzAO About HeartSciences HeartSciences is a healthcare information…

Continue Reading

MondayFeb 23, 2026 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” highlighting growing investor interest in clinical-stage platforms supported by existing human data. The editorial notes that programs demonstrating clinical activity offer clearer valuation benchmarks and reduced uncertainty compared with preclinical assets, positioning companies with diversified clinical pipelines, including oncology and CNS-focused targets such as TGF-β signaling and delivery-based approaches, to align with industry demand for validated mechanisms and strategic portfolio depth. To view the full press release, visit https://ibn.fm/cZmVn About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

Continue Reading

MondayFeb 23, 2026 9:20 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach

TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of a manuscript in Molecular Imaging and Biology detailing a novel tumor-selective immunotherapy strategy that activates RIG-I signaling within cancer cells while enabling non-invasive imaging of drug delivery. The study, conducted in collaboration with Michigan State University researcher Dr. Anna Moore, describes a template-directed RIG-I agonist approach leveraging overexpressed oncogenic microRNAs such as miRNA-21 to drive intracellular immune activation and reduce off-target toxicity, and highlights the potential clinical relevance of combining tumor-specific RNA templating with the company’s TTX nanoparticle delivery platform, which is currently under clinical evaluation. To view the full press release,…

Continue Reading

FridayFeb 20, 2026 3:04 pm

BioMedNewsBreaks — Mangoceuticals, Inc. (NASDAQ: MGRX) Reports 336% Sales Growth for $99 Monthly TRT Program 

Mangoceuticals (NASDAQ: MGRX) operating under the MangoRx and PeachesRx brands, announced initial success for its newly launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month, which includes doctor visits, consultations, lab work and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver, alongside oral formulations including PRIME by MangoRx powered by Kyzatrex, as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025.…

Continue Reading